Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-78934804 versus guselkumab in moderately to severely active ulcerative colitis
NL-OMON61428Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of guselkumab + golimumab, guselkumab and golimumab in autoimmune colitis (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Clinical remission at Week 48. Started Aug 2026; status: recruiting.
02
Drugs
guselkumab + golimumabguselkumabgolimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON61428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61428.